Paul Estrem is CFO at MELINTA THERAPEUTICS, INC. /NEW/ (MLNT). They have made 1 open-market trade across 1 company since 2018, most recently 2018-05-29.
CIK 0001722374
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MLNT | 10,000 | $5K |
Shares reported on the most recent Form 4, priced at the 2018-05-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLNT | BUY | 2018-05-29 | 2018-05-31 | $5.00 | $50K | +17.2% | -3.7% | -31.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.